Life Sciences executive with over 20 years of demonstrated leadership experience within commercial roles at innovative medical device companies such as ClearPoint Neuro (Nasdaq: CLPT), Volcano Corporation (Nasdaq: VOLC), Philips (NYSE: PHG) and Naviscan. Demonstrated track record of collaborating with a board of directors, CEOs and senior leadership team in investor relations activities and experience on teams that successfully raised new financing through strategic partnerships, venture capital, common stock public-offerings and multiple company exits via M&A such as Volcano Corporation to Philips for $1.2B, Naviscan to CMR Molecular Imaging, and Artemis to PE-backed Headlands Research. Adept at leading cross-functional product development teams, scaling product revenue and driving the successful new product commercialization of over 15+ new medical device and therapeutic products. Extensive leadership experience in driving product development and guiding commercial teams in the launch of complex and disruptive medical technologies, such as Volcano’s iFR® coronary physiology tool, and SmartFlow® ClearPoint Neuro’s landmark FDA De Novo Marketing Authorization for the only approved device to deliver the first-ever approved gene therapy for a CNS indication. Broad functional oversight of teams with responsibility for corporate strategy, business development, sales and marketing, clinical research, reimbursement, new product development, corporate communications and investor relations.